

04 Jun 2023 | News

Quick Listen: Scrip's Five Must-Know Things

by Ian Haydock

In this week's podcast edition of Five Must-Know Things: a preview of ASCO; Roche CEO on new opportunities; Sanofi sees success in MS; Phase II lupus win for AbbVie; and a Chinese product case study in psoriasis.

Join us for an audio catch-up on the major events in the biopharma industry over the past business week, as reported by *Scrip's* global team, in this podcast version of Five Must-Know Things.

This episode covers insights for the business week ended 2 June 2023, including: a preview of ASCO; [Roche Holding AG](#) pharma CEO on new opportunities; [Sanofi](#) sees success in MS; Phase II lupus win for [AbbVie Inc.](#); and a Chinese product case study in psoriasis.

This and all our other podcasts are available on the Pharma Intelligence channel on [Apple Podcasts](#), [Google Podcasts](#), [SoundCloud](#), [TuneIn](#) and [Spotify Podcasts](#), and via smart speakers if one of these platforms has been set up as your default podcast provider.

Stories mentioned in this episode:

(Also see "[ASCO Preview: Five Top Late-Breakers To Watch For](#)" - Scrip, 26 May, 2023.)

(Also see "[Roche Pharma CEO Graham On Growth Prospects, Policy Pressures, Alzheimer's And More](#)" - Scrip, 25 May, 2023.)

(Also see "[Sanofi Moves Up In MS With Frexalimab Success](#)" - Scrip, 31 May, 2023.)

(Also see "[AbbVie's Rinvoq Succeeds Against The Odds In Phase II Lupus Trial](#)" - Scrip, 31 May, 2023.)

(Also see "[Falling At The Start Line: Chinese Firms Face Multiple Commercial Challenges Beyond Price, Coverage](#)" - Scrip, 30 May, 2023.)

[Click here to explore this interactive content online](#) 